NCT05453435Active, not recruitingPhase 2
Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)
Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) (REHEB)：a Single Arm, Open Label, Multi-center Phase II Study
Source: ClinicalTrials.gov · Last updated 22 May 2026
Brief summary (registry, in English)
This phase 2 trial aims to evaluate the efficacy of entecavir prophylacxis for hepatitis B virus (HBV) reactivation that continues until 6 months after completing CD20 monoclonal antibody therapy in patients with CD20-positive B-cell lymphomas and resolved hepatitis B (negative hepatitis B surface antigen, positive hepatitis B core antibody).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- First submitted
- 2 Jul 2022
- Start date
- 15 Jul 2022
- Primary completion date
- Dec 2026
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Hepatitis B
- NCT number
- NCT05453435
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 84
- From 15 Jul 2022 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous chemotherapy or radiotherapy for lymphoma;
Other illness
- Positive HBsAg or HBV-DNA higher than the detection limit at baseline;
- Other primary liver diseases, such as chronic hepatitis C, hepatitis D, autoimmune hepatitis, Wilson' s disease or primary biliary cirrhosis;
- History of immunodeficiency, including positive HIV, or other acquired congenital immunodeficiency disease, or history of organ transplantation.
Other
- Pregnant or lactating women;
Who the study is looking for
- Histopathologically confirmed CD20 positive B-cell lymphoma;
- Plan to receive first-line anti-lymphoma therapy containing CD20 monoclonal antibodies;
- Negative HBsAg, HBV-DNA lower than the detection limit and positive anti-HBC at baseline;
- Total bilirubin less than 1.5X the upper limit of normal (ULN), AST and ALT less than 2.5X ULN;
- ECOG PS: 0\~2;
- Estimated survival time \>3 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.